Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.
UCB Presents 4-Year Data on Bimekizumab for Plaque Psoriasis
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
Psoriasis within the US Hispanic Population: What Can Be Done to Diversify Clinical Data?
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
‘Next-Generation TYK2 Inhibitor’: Insights into Zasocitinib
FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis